
-
BioNTech SE NasdaqGS:BNTX BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Location: An der Goldgrube 12, Mainz, 55131, Germany | Website: https://www.biontech.de | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
9.215B
Cash
14.11B
Avg Qtr Burn
-63.93M
Short % of Float
5.74%
Insider Ownership
62.69%
Institutional Own.
22.26%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COMIRNATY (BNT162b2) Details COVID-19, Infectious disease | Approved Quarterly sales | |
BNT323/DB-1303 Details Cancer, Breast cancer | Phase 3 Data readout | |
Combined modified mRNA vaccine (Influenza A/B + COVID-19) Details COVID-19, Infectious disease, Influenza | Phase 3 Update | |
BNT323/DB-1303 Details Cancer, HER2-expressing cancers, Endometrial cancer | Phase 3 Initiation | |
Autogene cevumeran (BNT122) (w/ with atezolizumab and chemotherapy) Details Solid tumor/s, Pancreatic cancer, Cancer | Phase 2 Data readout | |
BNT113 Details Head and neck cancer, Human papillomavirus | Phase 2 Data readout | |
BNT116 +/- cemiplimab Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
BNT316 (ONC-392) Details Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 2 Data readout | |
Autogene Cevumeran (BNT122) (w/ pembrolizumab) Details Non-small cell lung carcinoma, Solid tumor/s, Bladder cancer, Melanoma | Phase 2 Interim update | |
BNT327/PM8002 Details Cancer, Solid tumor/s, Cervical cancer, Platinum-resistant ovarian cancer | Phase 2 Update | |
Autogene cevumeran (BNT122) (RO7198457) Details Solid tumor/s, Colorectal cancer | Phase 2 Update | |
BNT311/GEN1046 +/- pembrolizumab Details Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 2 Update | |
BNT111 w/ LIBTAYO (cemiplimab). Details Melanoma, Cancer | Phase 2 Update | |
BNT325 (DB-1305) Details Cancer, Non-small cell lung carcinoma, Solid tumor/s, Platinum-resistant ovarian cancer | Phase 1/2 Data readout | |
BNT166 Details Vaccine, Smallpox | Phase 1/2 Data readout | |
BNT312/GEN1042 Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
BNT324/DB-1311 Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
BNT211 Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
BNT323/DB-1303 Details Cancer, Solid tumor/s, HER2-expressing cancers | Phase 1/2 Update | |
BNT167 Details Vaccine, Shingles | Phase 1/2 Update | |
BNT327/PM8002 Details Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 1b Update | |
BNT164 Details Vaccine, Tuberculosis | Phase 1 Data readout | |
BNT116 +/- cemiplimab Details Cancer, Non-small cell lung carcinoma, Solid tumor/s | Phase 1 Data readout | |
BNT326/YL202 Details Cancer, HER2-expressing cancers, Breast cancer, Non-small cell lung carcinoma | Phase 1 Update | |
BNT221 Details Melanoma | Phase 1 Update |